Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorABAD, ETNA
dc.contributor.authorSandoz, Jeremy
dc.contributor.authorRomero Sola, Gerard
dc.contributor.authorZadra, Ivan
dc.contributor.authorUrgel-Solas, Julia
dc.contributor.authorBorredat, Pablo
dc.date.accessioned2024-05-22T12:19:55Z
dc.date.available2024-05-22T12:19:55Z
dc.date.issued2024-04-29
dc.identifier.citationAbad E, Sandoz J, Romero G, Zadra I, Urgel-Solas J, Borredat P, et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability. J Exp Clin Cancer Res. 2024 Apr 29;43(1):127.
dc.identifier.issn1756-9966
dc.identifier.urihttps://hdl.handle.net/11351/11488
dc.descriptionAneuploidy; Cancer; Genomic instability
dc.description.abstractBackground TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers. Methods Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis. Results Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability. Conclusions Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression.
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.ispartofseriesJournal of Experimental & Clinical Cancer Research;43(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectPulmons - Càncer - Aspectes genètics
dc.subjectProteïnes supressores de tumors
dc.subject.meshAdenocarcinoma of Lung
dc.subject.mesh/genetics
dc.subject.meshTumor Suppressor Protein p53
dc.subject.meshGenomic Instability
dc.titleThe TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13046-024-03045-4
dc.subject.decsadenocarcinoma de pulmón
dc.subject.decs/genética
dc.subject.decsproteína supresora de tumor p53
dc.subject.decsinestabilidad genómica
dc.relation.publishversionhttps://doi.org/10.1186/s13046-024-03045-4
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Abad E, Sandoz J, Zadra I, Borredat P] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. [Romero G] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Urgel Solas J] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
dc.identifier.pmid38685100
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record